Kelly Vazquez
Acute Care · Huntsville, ALNPI 1215385380
Payments from drug & device makers
Across 511 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$1K
- Insmed, Inc.$918
- Regeneron Healthcare Solutions, Inc.$766
- Takeda Pharmaceuticals U.S.A., Inc.$654
- plus $6K from 29 others
What the payments were for
- Food & beverage$11,61599%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,590 |
| AstraZeneca | 38 | $1,100 |
| Sanofi | 33 | $1,033 |
| Insmed, Inc. | 43 | $918 |
| Regeneron Healthcare Solutions, Inc. | 30 | $766 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $654 |
| Boehringer Ingelheim | 21 | $574 |
| Grifols USA, LLC | 23 | $563 |
| Pulmonx Corporation | 5 | $400 |
| Axsome Therapeutics, Inc. | 25 | $367 |
| Harmony Biosciences LLC | 13 | $354 |
| Mylan Specialty L.p. | 14 | $307 |
| Jazz Pharmaceuticals Inc. | 11 | $267 |
| Avadel CNS Pharmaceuticals, LLC | 14 | $254 |
| Inspire Medical Systems, Inc. | 5 | $252 |
| Novartis | 13 | $238 |
| Pfizer | 14 | $223 |
| Actelion Pharmaceuticals US, Inc. | 5 | $208 |
| Genentech USA, Inc. | 11 | $198 |
| Verona Pharma, Inc. | 9 | $178 |
| Pharming Healthcare, Inc. | 2 | $145 |
| Viatris Specialty LLC | 7 | $140 |
| Baxter Healthcare | 8 | $139 |
| Merck | 8 | $134 |
| United Therapeutics Corporation | 7 | $124 |
| Philips North America LLC | 7 | $120 |
| Amgen | 4 | $88 |
| Genentech, Inc. | 1 | $84 |
| Bayer | 4 | $83 |
| Lilly USA, LLC | 3 | $48 |
| Melinta Therapeutics, LLC | 2 | $38 |
| CSL Behring | 1 | $35 |
| Inogen, Inc. | 2 | $28 |
| Gilead | 1 | $18 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$442
- CHARTIS CATHETER$317
- ZEPHYR DELIVERY CATHETER$317
- ZEPHYR ENDOBRONCHIAL VALVE$317
- PULMONX CHARTIS TABLET CONSOLE$317
- DUPIXENT$224
- AIRSUPRA$200
- FASENRA$200
- TEZSPIRE$200
- Inspire$144
- JOENJA$122
- UPTRAVI$121
- OPSUMIT$121
How this compares
$11,682 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $75,861 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $30,969 |
| Arnuity ElliptaFluticasone Furoate | 40 | $13,321 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,764 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $10,113 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $8,722 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $7,931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 130 | $5,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,217 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $3,081 |
| Azelastine Hcl | 45 | $1,904 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,843 |
| Famotidine | 93 | $1,793 |
| Cefdinir | 63 | $1,691 |
| Fluticasone Propionate | 76 | $1,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $1,590 | $101,946135 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,100 | $41,08273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.
Other acute care in Huntsville
- April KlarHuntsville$13K
- Stephanie TateHuntsville$13K
- Summer SlaterHuntsville$12K
- Tiffany RentzHuntsville$11K
- Britanie MooreHuntsville$9K
- Trey WilsonHuntsville$8K
- Esther HambrickHuntsville$8K
- Jessica BurkeenHuntsville$8K
- Alyssa EzellHuntsville$8K
- Ashley WrightHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.